The latest research suggests that the recombinant shingles vaccine may offer additional benefits. It appears to reduce the ...

The risk for incident gout following RZV exposure was not increased among adults aged 50 years or older, according to study findings.

Please see full Prescribing Information for AREXVY. About SHINGRIX(Recombinant Zoster Vaccine or RZV) SHINGRIX is a non-live, recombinant subunit vaccine indicated for the prevention of shingles ...

Researchers conducted an observational study to compare the risk for dementia associated with both the live and recombinant shingles vaccines.

GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine, Shingrix ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

The risk for incident gout following RZV exposure was not increased among adults aged 50 years or older, according to study findings.

Please see full Prescribing Information for AREXVY. About SHINGRIX(Recombinant Zoster Vaccine or RZV) SHINGRIX is a non-live, recombinant subunit vaccine indicated for the prevention of shingles in ...

Among the 461,323 individuals who received at least 1 RZV dose, 1264 experienced new-onset gout within 60 days postvaccination; 302 patients were determined to have incident cases of gout, with no ...

7 An estimated one million people develop shingles annually in the US. 8 About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in ...

7 An estimated one million people develop shingles annually in the US. 8 About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in the ...